secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093304
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx Q2 net loss $72.7M; revenue negative after RELYVRIO withdrawal; avexitide acquisition
--------------------------------------------------------------------------------

- Q2 net loss $72.7M ($1.07/share) vs net income $22.1M ($0.31) a year ago; revenue negative $(1.0)M after RELYVRIO/ALBRIOZA withdrawal.
- Cash $309.8M at June 30, down from $373.3M at March 31; runway into 2026.
- Acquired avexitide (GLP-1 antagonist) with FDA Breakthrough Therapy; PBH Phase 3 plan Q1 2025.
- Restructuring $22.9M largely severance; headcount reduced after PHOENIX failure and product discontinuation.
- R&D down to $23.3M, SG&A to $21.6M; cost cuts and pipeline shift from RELYVRIO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000095017024093304/0000950170-24-093304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000095017024093304/amlx-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer